COVID-19 RESPONSE - We are committed to supporting our scientific community during this pandemic. Learn more 

Curve

Join Gargi Roy of AstraZeneca’s Stem Cell Therapy team to explore high throughput human stem cell engineering workflows that automate monoclonality assurance and accelerate research timelines.

In recent years regenerative cell therapies utilizing the pluripotency of hESCs or iPSCs are gaining ground and hold promise to outpace conventional treatment options for cardiac, kidney, liver, neuronal and other diseases in years to come. However, engineering and maneuvering these very unique cell types remains challenging.

While the regulatory guidelines for this novel therapeutic modality are still being worked out, Molecular Devices introduced a hSC engineering workflow with the CloneSelect® Single-Cell Printer and CloneSelect® Imager. This enables high throughput screening of engineered iPS and ES clones by preserving traceability with assurance of monoclonality while maintaining their normal genetic integrity, pluripotency and cellular functionality. The implementation of these technologies enabled the AstraZeneca team to build a unique collection of hundreds of clonal iPSC and ESC lines to develop a deeper understanding regenerative therapies to come.

Learning Objectives

  • Understand how the CloneSelect Single-Cell Printer is an effective tool for single cell isolation of IPSCs and ESCs.
  • Explore how the combination of CloneSelect Single-Cell Printer and CloneSelect Imager offers confirmation of monoclonality assessments.
  • Discover how Clonal ESCs and iPSCs isolated by CloneSelect Single-Cell Printer maintain genomic stability and pluripotency for many generations and can be effectively programmed to differentiate into three germ layers and organ specific cell types.

Please register to view the webinar